Elbasvir; Grazoprevir Patent Expiration
Elbasvir; Grazoprevir is Used for treating patients infected with hepatitis C virus. It was first introduced by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc
Elbasvir; Grazoprevir Patents
Given below is the list of patents protecting Elbasvir; Grazoprevir, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zepatier | US8871759 | Inhibitors of hepatitis C virus replication | May 04, 2031 | Msd Sub Merck |
| Zepatier | US7973040 | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors | Jul 24, 2029 | Msd Sub Merck |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Elbasvir; Grazoprevir's patents.
Latest Legal Activities on Elbasvir; Grazoprevir's Patents
Given below is the list recent legal activities going on the following patents of Elbasvir; Grazoprevir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2022 | US7973040 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Mar, 2022 | US8871759 |
| Patent Term Extension Certificate Critical | 10 Dec, 2021 | US7973040 |
| Notice of Final Determination -Eligible | 09 Mar, 2021 | US7973040 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Dec, 2018 | US7973040 |
| FDA Final Eligibility Letter Critical | 10 Oct, 2018 | US7973040 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Mar, 2018 | US8871759 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2018 | US7973040 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2017 | US7973040 |
| Second letter to regulating agency to determine regulatory review period | 05 Sep, 2017 | US7973040 |
Elbasvir; Grazoprevir's Family Patents
